A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
While the impact of COVID-19 on the respiratory system of infected patients is well known, research shows that impact on the kidneys can be just as concerning. Acute Kidney Injury (AKI), an abrupt decrease in kidney function that frequently affects hospitalized patients and has been associated with higher mortality, is also frequent among hospitalized COVID-19 patients. However, little is known about the actual impact of AKI on healthcare resource utilization and costs among hospitalized patients with COVID-19.
There is an urgent need to understand the clinical and economic consequences associated with AKI in hospitalized patients with COVID-19 to better inform treatment decisions and healthcare resource allocation.
bioMérieux, a global leader in in vitro diagnostics, joined forces with PINC AI™ Applied Sciences (PAS), the research and analytics division of Premier. Using the PINC AI™ Healthcare Database (PHD), they pinpointed real-world evidence on the consequences of AKI in hospitalized COVID-19 patients.
The Research team selected the PHD, based on the breadth and depth of patient data, as the data source for its retrospective real-world cohort study aimed to compare characteristics, clinical outcomes, healthcare resource utilization (HRU) and costs for hospitalized U.S. COVID-19 patients aged ≥ 18 years, with and without AKI during their initial hospitalization. The study time took place between April 1 and Oct. 31, 2020, with 30-day follow-up outcomes and 365-day lookback for comorbidities.
Researchers found:
The results of this study, presented at the European Society of Intensive Medicine’s (ESICM) annual conference, LIVES on Oct. 4 and referenced here on page 2, support the implementation of preventive measures to decrease the incidence of AKI among hospitalized COVID-19 patients and reduce the utilization of costly resources such as dialysis and the ICU.
PINC AI Applied Sciences partners with life sciences, academia, government agencies, and healthcare insurers and providers, enabling them with robust PHD data for real-world applied research and analytics, science implementation and prospective research and clinical trials that help inform evidence-based practices and improve quality, safety and cost-effectiveness of care.
The PHD comprises more than 20 years of de-identified data from over 1,030 hospitals spanning multiple therapeutic areas and quality improvement areas. Currently, the PHD contains data from more than 1 billion inpatient and hospital-based outpatient encounters.
In addition to the standardized data contained in the PHD, the PAS team developed a Special Release of the PHD (PHD-SR) to help drive COVID-19 research. The PHD-SR has shortened the data lag time from five months to two weeks, making it the ideal source of data for studying the disease. Today, the PHD-SR contains real-world data representing more than 2.4 million inpatient and hospital-based outpatient encounters with a COVID-19 diagnosis.
Learn More: Discover how the PHD has fueled leading COVID-19 research conducted by the PAS research team, Centers for Disease Control and Prevention, the National Institutes of Health and others.
Find out more about the capabilities of the PHD as they relate to COVID-19 data.
The insights you need to stay ahead in healthcare: Subscribe to Premier’s Power Rankings newsletter and get our experts’ original content delivered to your inbox once a month.